Cited by 949Protein Kinase Regulation and GTPase SignalingProtein Degradation and InhibitorsCancer Mechanisms and Therapy

The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.

Drugging the ‘undruggable’ cancer targets

Open access

Dang, Chi V., Reddy, E. Premkumar, Shokat, Kevan M., Soucek, Laura·2017·Nature Reviews Cancer

DOI 10.1038/nrc.2017.36PMC PMC5945194

Open this paper in CoChat — free account

Abstract

The term 'undruggable' was coined to describe proteins that could not be targeted pharmacologically. However, progress is being made to 'drug' many of these targets, and therefore more appropriate terms might be 'difficult to drug' or 'yet to be drugged'. Many desirable targets in cancer fall into this category, including the RAS and MYC oncogenes, and pharmacologically targeting these intractable proteins is now a key challenge in cancer research that requires innovation and the development of new technologies. In this Viewpoint article, we asked four scientists working in this field for their opinions on the most crucial advances, as well as the challenges and what the future holds for this important area of research.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/nrc.2017.36

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cancer Genome Landscapes
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Selective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262
MYC on the Path to Cancer
Dang, C. V. (2012) · Cell · doi:10.1016/j.cell.2012.03.003 · Cited by 3,390
Self-citation
Peptide therapeutics: current status and future directions
Fosgerau, K., & Hoffmann, T. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.10.003 · Cited by 3,160
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Antonarakis, E. S., Lu, C., Wang, H., Luber, B., Nakazawa, M., Roeser, J. C., Chen, Y., Mohammad, T. A., Chen, Y., Fedor, H. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315815 · Cited by 2,710
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
Self-citation
Drugging the undruggable RAS: Mission Possible?
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997
Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells
Commisso, C., Davidson, S. M., Soydaner-Azeloglu, R. G., Parker, S. J., Kamphorst, J. J., Hackett, S., Grabocka, E., Nofal, M., Drebin, J. A., Thompson, C. B., et al. (2013) · Nature · doi:10.1038/nature12138 · Cited by 1,683
Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer
Watson, P. A., Arora, V. K., & Sawyers, C. L. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4016 · Cited by 1,536

Flagged first, then by citations

Show all 57 references

Sorted by citations

Items 701–800 of 949

CDK12-Mediated Phosphorylation of FOXA1 Promotes Prostate Cancer Progression via the MDM2–p53 Axis
Yan, B., Huang, M., Wang, J., Lei, H., Tong, T., Xu, B., Cao, F., Teng, Q., Huang, J., Guan, Y., et al. (2025) · Research · doi:10.34133/research.0990 · Cited by 2
Novel cyclic C5-curcuminoids possess anticancer activities against HeLa cervix carcinoma, HEC-1A adenocarcinoma, and T24 bladder carcinoma cells
Pandur, E., Schenk, P., Kulcsár, G., Gulyás‐Fekete, G., Sipos, K., & Huber, I. (2025) · Cancer Cell International · doi:10.1186/s12935-025-04077-2 · Cited by 2
Discovery of small-sized tris-aryl imidazoles as bifunctional ligands for c-Myc and KRAS G-quadruplexes
Liu, X.-Z., Wang, X.-D., & Hu, M.-H. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.109656 · Cited by 2
A Dicer-Activatable Aptamer-Adamantane/siRNA (AptHyT-siRNA) Chimera Enables Synergistic Targeted Protein Degradation and mRNA Silencing
Chen, X., Gao, Q., Yang, L., Mou, S., Wang, R., & Han, D. (2026) · Nano Letters · doi:10.1021/acs.nanolett.6c00010 · Cited by 2
High-PepBinder: A pLM-Guided Latent Diffusion Framework for Affinity-Aware Target-Specific Peptide Design
Mao, Q., Zhai, S., Cao, S., Zhu, R., Xu, W., Zhang, C., Ning, Z., Guo, J., & Duan, H. (2026) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.6c00253 · Cited by 2
Proteolysis-targeting chimera (PROTAC) in cancer: design principles and applications on “undruggable” targets
Lu, X., Qin, J., Dong, S., Yuan, Y., Zhang, Z., Zhang, B., Chen, X., Gan, X., Liang, H., & Liu, F. (2026) · Biomarker Research · doi:10.1186/s40364-026-00937-9 · Cited by 3
Computationally Evidence‐Grounded Sequence‐First Design of Peptide Binders
Ding, W. (2026) · Advanced Science · doi:10.1002/advs.77125 · Cited by 2
Predicting E3 Ubiquitin Ligases as Possible Promising Biomarkers for Brain Tumors
Joshi, V., Upadhyay, A., Amanullah, A., Mishra, R., & Mishra, A. (2019) · Springer eBooks · doi:10.1007/978-981-13-5877-7_4 · Cited by 2
An alternative and efficient synthesis of MLN4924, a selective NEDD8 inhibitor
Kim, H., Hyun, Y. E., Jarhad, D. B., Yu, J., & Jeong, L. S. (2019) · Organic Chemistry Frontiers · doi:10.1039/c9qo00507b · Cited by 2
Receptor–ligand pair typing and prognostic risk model of response or resistance to immune checkpoint inhibitors in lung adenocarcinoma
Mao, S., Zeng, L., Yang, Y., Liu, Z., & Zhang, L. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1170942 · Cited by 2
Design, synthesis, and analysis of macrobicyclic peptides for targeting the Gαi protein
Pepanian, A., Binbay, F. A., Pei, D., & Imhof, D. (2024) · Journal of Peptide Science · doi:10.1002/psc.3565 · Cited by 2
BRD4L cooperates with MYC to block local tumor invasion via suppression of S100A10
Ma, Y., Liu, N., Shi, Y., Ma, S., Wang, Y., Zheng, W., Sun, R., Song, Y., Chen, M., Qu, L., et al. (2024) · Cellular Signalling · doi:10.1016/j.cellsig.2024.111173 · Cited by 2
In silico identification of putative druggable pockets in PRL3, a significant oncology target
Bennett, G. M., Starczewski, J., & Cerna, M. V. C. D. (2024) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2024.101767 · Cited by 2
Structure‐Based Design of Bicyclic Helical Peptides That Target the Oncogene β‐Catenin
Yeste‐Vázquez, A., Paulussen, F. M., Wendt, M., Klintrot, R., Schulte, C., Wallraven, K., van Gijzel, L., Simeonov, B., van der Gaag, M., Gerber, A., et al. (2024) · Angewandte Chemie · doi:10.1002/ange.202411749 · Cited by 2
Oxidative protein damage negatively affects protein-protein interaction: The case of KRAS-cRAF
Dimlić, M. R., Raić, S., Močibob, M., Maršić, Ž. S., Yao, Z., Radman, M., & Štagljar, I. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.150792 · Cited by 3
Combinatorial Anti-Cancer Effect of Polypurine Reverse Hoogsteen Hairpins against KRAS and MYC Targeting in Prostate and Pancreatic Cancer Cell Lines
Valiuska, S., Elder, K. K., McKay, S. J., Ciudad, C. J., Noé, V., & Brooks, T. A. (2024) · Genes · doi:10.3390/genes15101332 · Cited by 2
Unraveling atomic-scale mechanisms of GDP extraction catalyzed by SOS1 in KRAS-G12 and KRAS-D12 oncogenes
Hu, Z., & Martí, J. (2024) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2024.109599 · Cited by 2
Excessive MYC Orchestrates Macrophages induced Chromatin Remodeling to Sustain Micropapillary‐Patterned Malignancy in Lung Adenocarcinoma
Song, X., Pan, Z., Zhang, Y., Yang, W., Zhang, T., Wang, H., Chen, Y., Yu, X., Ding, H., Li, R., et al. (2025) · Advanced Science · doi:10.1002/advs.202403851 · Cited by 2
Enhancing access to innovative cancer drugs: Cross-sector consensus on a way forward to benefit patients
Hoey, R., Sharpe, E., Kukula, A. K., & Workman, P. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.12.015 · Cited by 2
Synthesis and Evaluation of 4′‐C‐(S) and 4′‐C‐(R)‐2‐Aminopropoxy−Thymidine‐Modified DNAs for Thermal Stability, RNase H Digestion, and Nuclease Resistance
Onishi, S., Chandela, A., & Ueno, Y. (2024) · ChemistrySelect · doi:10.1002/slct.202305090 · Cited by 2
Immunoliposomes-mediated small interfering RNA therapy: A novel approach for the treatment of cancer.
Khan, A. (2019) · PubMed Central · Cited by 2
The contribution of MYC and PLK1 expression to proliferative capacity in diffuse large B-cell lymphoma
Oon, M. L., Hoppe, M. M., Shuangyi, F., Phyu, T., Phuong, H. M., Tan, S., Hue, S. S., Wang, S., Poon, L. M., Chan, H. L. E., et al. (2019) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2019.1633629 · Cited by 2
Selective targeting of KRAS-driven lung tumorigenesis via unresolved ER stress
Shimomura, I., Watanabe, N., Yamamoto, T., Kumazaki, M., Tada, Y., Tatsumi, K., Ochiya, T., & Yamamoto, Y. (2021) · JCI Insight · doi:10.1172/jci.insight.137876 · Cited by 2
Computational drug repositioning of bortezomib to reverse metastatic effect of GALNT14 in lung cancerPreprint
Kwon, O., Lee, H., Kong, H., Park, J. E., Lee, W., Kang, S., Kim, S., Kim, W., & Cha, H. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/394163 · Cited by 2
Id proteins promote a cancer stem cell phenotype in triple negative breast cancer via negative regulation of Robo1Preprint
Teo, W. S., Holliday, H., Karthikeyan, N., Cazet, A., Roden, D. L., Harvey, K., Konrad, C. V., Murali, R., Varghese, B. A., Archana, P. T., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/497313 · Cited by 2
Clinical sequencing identifies potential actionable alterations in a high rate of urachal and primary bladder adenocarcinomasPreprint
Váradi, M., Nagy, N. T., Reis, H., Hadaschik, B. A., Niedworok, C., Módos, O., Szendrői, A., Ablat, J., Black, P. C., Keresztes, D., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1757372/v1 · Cited by 2
SALLB not targeted by IMiDs is important for maintenance of liver cancer cellsPreprint
Vu, K. A. L., Moein, S., Kumari, K., Liu, B. H., Gao, C., Liu, M., Dai, M.-Y., Liu, Z., Li, F., Tang, J., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.07.07.548071 · Cited by 2
Characterization of cancer-driving nucleotides (CDNs) across genes, cancer types, and patientsPreprint
Zhang, L., Deng, T., Liufu, Z., Chen, X., Wu, S., Liu, X., Shi, C., Chen, B., Hu, Z., Cai, Q., et al. (2024) · eLife · doi:10.7554/elife.99341 · Cited by 2
Unveiling Candidate Drivers in Cancer Progression Using Somatic-IV AnalysisPreprint
Zhang, W., Ghaffari, S., Browne, A. J., Macintosh, C., Lu, X., Dang, H. M., Lopez, G., & Wang, K. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.02.20.638369 · Cited by 2
Sulfinyl Aziridines as Stereoselective Covalent Destabilizing Degraders of the Oncogenic Transcription Factor MYCPreprint
Rosen, H. T., Li, K., Li, E. L., Currier, B., Brittain, S. M., García, F., Beard, D. C., Haenni‐Holzinger, S., Dovala, D., McKenna, J. M., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.02.24.639755 · Cited by 2
Therapeutic peptidomimetics: targeting the undruggable space
Mabonga, L., Masamba, P., & Kappo, A. P. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-820141-1.00026-1 · Cited by 1
BET Bromodomain Inhibitors as an Emerging Class of Anticancer Agents
Yasser, R., Arafa, K. K., Sedky, N. K., Sidaros, K. R., & Arafa, R. K. (2023) · Springer eBooks · doi:10.1007/978-3-030-80962-1_401-1 · Cited by 1
Improving oral absorption of a rapidly crystallizing parent drug using prodrug strategy: Comparison of phosphate versus glycine based prodrugs
Indulkar, A. S., Slade, R. T., Jana, N., Frey, R. R., Penning, T. D., Lai, A., & Leblanc, A. F. (2024) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2024.09.012 · Cited by 1
KRAS G12C Inhibitors: New Drugs, A New Hope
Singhal, S., Schokrpur, S., Gandara, D. R., & Riess, J. W. (2024) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2024.09.1383 · Cited by 1
DNMDA: Deep Non-negative Matrix Factorization with Multi-level Integration for MiRNA-Drug Interaction Prediction
Qi, Y., Yang, J., Huang, Y., You, Z.-H., Zhang, Z., Hu, L., Zhou, X., & Hu, P. (2024) · IEEE International Conference on Bioinformatics and Biomedicine (BIBM) · doi:10.1109/bibm62325.2024.10822381 · Cited by 1
Tumor‐Selective Gene Therapy: Using Hairpin DNA Oligonucleotides to Trigger Cleavage of Target RNA by Endogenous flap endonuclease 1 (FEN 1) Highly Expressed in Tumor Cells
Wang, C., Wang, C., Xiao, C., Zhang, W., Guo, Y. H., Qu, M., Song, Q., Qi, X., & Zou, B. (2025) · Small · doi:10.1002/smll.202410146 · Cited by 1
HTS Identifies NUP98-KDM5A-PHD3 Domain Ligands with Novel Scaffolds
Lin, W., Slavish, P. J., Phillips, A. H., Trotter, M., Yang, G., Chai, S. C., Churion, K. A., Ochoada, J., Das, S., Shelat, A. A., et al. (2025) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5c00116 · Cited by 1
RNA activation of CEBPA improves leukemia treatment
Kovecses, O., Sharif-Askari, B., González‐Losada, C., Reebye, V., Ryan, B. M., Kwok, A., Habib, N., Luedtke, N. W., Mercier, F., & McKeague, M. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102611 · Cited by 1
A Melittin-Derived Peptide with Improved Cytosolic Delivery Efficiency through Caveolae- and Actin-Mediated Endocytosis
Kawaguchi, Y., Tamemoto, N., Uehata, Y., Miyazaki, Y., Shinoda, W., & Futaki, S. (2025) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c25-00479 · Cited by 1
Transcriptional Condensates: Epigenetic Reprogramming and Therapeutic Targets in Hematologic Malignancies
Qiu, K., Yin, Q., Zang, C., & Tao, J. (2025) · Cancers · doi:10.3390/cancers17193148 · Cited by 1
Targeting RAS for Cancer Treatment: What a Long, Strange Trip It's Been
Cox, A. D., & Der, C. J. (2025) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-071024-082459 · Cited by 1
Computational approaches enhance the design of molecular glue degraders for undruggable proteins
Deshani, S. G. M. A., Madushani, G. R. D. S., Karunaratne, V., Vinit, K., & Hao, G. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104577 · Cited by 2
BET Bromodomain Inhibitors as an Emerging Class of Anticancer Agents
Yasser, R., Arafa, K. K., Sedky, N. K., Sidaros, K. R., & Arafa, R. K. (2025) · Springer eBooks · doi:10.1007/978-3-032-00771-1_401 · Cited by 2
From rare to prevalent: dawn of the RNA therapeutics era
Zhou, J. L., & Shu, E. (2025) · Targetome · doi:10.48130/targetome-0025-0005 · Cited by 1
Target Class Repurposing Across Membrane Transporter Families Provides Privileged Ligands to Address Specific and Undruggable Pharmacological Targets
Rafehi, M., Tägl, F., Arlt, N. S., Neif, M., Stefan, K., Al-khalil, W. I., Busch, H., Möller, M., König, J., Namasivayam, V., et al. (2026) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00430 · Cited by 1
Harnessing reactive oxygen species for precision medicine: ROS-Activatable PROTACs for lung Cancer
Olazábal-Morán, M., Blázquez-Barbadillo, C., Pérez-Izquierdo, E., Muñoz-Silva, M., & Garrido, A. (2026) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2026.115840 · Cited by 2
Cytidinyl/Cationic Lipids-siRNA Delivery Silences MYC to Reprogram Macrophages and Circadian Rhythm for Cancer Treatment
Zhou, X., Yu, X., Qiu, K., Hong, J., Sun, M., Yang, L., & Yang, Z. (2026) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c01718 · Cited by 1
Analysis of binding modes for direct pan-specific inhibition of mutant forms of guanosine triphosphatase KRAS and prospects for targeting various allosteric sites
Shkil, D. O., Eliseev, I. A., Ivanov, R. A., & Balakin, K. V. (2026) · Russian Chemical Bulletin · doi:10.1007/s11172-026-4863-z · Cited by 1
Contemporary Developments in PROTACs for Cancer Management: An In-Depth Review
Rahaman, S. A., Venkateswarlu, G., Patel, S., Mishra, P. S., Kumar, R., & Parvez, N. (2026) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266384226251013054011 · Cited by 1
KRAS and MYC synergistic inhibition: a powerful strategy targeting KRAS-mutant cancers
Yan, M., Liu, K., Xu, J., Liu, Y., Ji, L., & Zhang, S. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02659-w · Cited by 1
Nucleic Acid Therapeutics for “Undruggable” Cancer Targets: Mechanisms, Challenges, and Prospects
Xu, F., Wang, K. J., 卢开忠, Hou, T., Chen, Y., Wang, X., & Jin, H. (2026) · Advanced Science · doi:10.1002/advs.75837 · Cited by 3
Toosendanin suppresses acute myeloid leukemia by targeting DDX5/c-Myc axis to inhibit protein synthesis
He, X., Chen, Z., Luo, J., Chen, H., Hou, Y., Liu, D., & Liu, Y. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-08339-z · Cited by 1
Lysosome‐Targeting Chimeras (LYTACs): From Modular Design Principles to Diverse Therapeutic Applications
Zhou, Z., Niu, Q., Yu, X., Yang, C. J., & Zhu, Z. (2026) · Chemistry - A European Journal · doi:10.1002/chem.71255 · Cited by 1
Extracellular and membrane-targeted protein degradation (emTPD): Mechanisms, design frameworks, and therapeutic opportunities
Zhang, K., Qiu, F., Lü, A., & Liang, C. (2026) · The Innovation Drug Discovery · doi:10.59717/j.xinn-drugdisc.2026.100024 · Cited by 1
Self-Splicing RNA Platform Encodes Twin PROTACs for Dual-E3 Ligase Recruitment and Programmable Protein Degradation
Ding, J., Wang, S., Tang, Z., Li, Y., Zhang, P., Song, Z., Luo, X., & Zhang, X. (2026) · Journal of the American Chemical Society · doi:10.1021/jacs.6c11759 · Cited by 1
Artificial intelligence empowers targeted protein degradation: Core technological innovations, multi‐scenario applications, and translational prospects
Qin, S., Peng, R., Zhang, G., Yan, S., Xiao, J., Liu, Z., Tan, Z., Xie, Q., Li, S., Luo, W., et al. (2026) · Smart Molecules · doi:10.1002/smo2.70089 · Cited by 2
Subcellular photochemistry for precision spatial protein targeting
Liu, M., Xiong, X., Zhang, A., & Zou, T. (2026) · Nature Reviews Chemistry · doi:10.1038/s41570-026-00864-1 · Cited by 1
Targeted protein degradation dismantles undruggable targets to reverse immune evasion and therapy resistance in cancer
张富荣, Wang, Q., Li, M., Wang, T., Lei, P., Huang, T., & Wu, Z. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1935909 · Cited by 1
Positive selection screen identifies natural product β-catenin inactivators
Boudreau, M. W., Freire, V. F., Corbett, S. C., Martínez-Fructuoso, L., Shenoy, S. R., Yu, W., Kumar, R., Thornburg, C. C., Akee, R. K., Peyser, B. D., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2625189123 · Cited by 1
Tryptoline stereoprobe elaboration identifies inhibitors of the GRPEL1–HSPA9 complex
Hayward, R. E., Berkeley, R. F., Gao, Z., Garhammer, M., Morizono, M. A., Njomen, E., Li, H., DeMeester, K. E., Cociorva, V., Herzik, M. A., et al. (2026) · Nature Chemical Biology · doi:10.1038/s41589-026-02348-1 · Cited by 5
Relación de los genes supresores de tumores y los oncogenes en el desarrollo del Cáncer
Lucero, P. A. F., Terán, D. N. K. M., Peralta, D. F. G., Angamarca, J. V. T., Loachamin, M. G. G., Zambrano, M. I. R., Ramón, Á. K. C., & Joaquín, M. G. A. (2023) · Brazilian Journal of Health Review · doi:10.34119/bjhrv6n3-320 · Cited by 1
Oncogenic Proteomics Approaches for Translational Research and HIV-Associated Malignancy Mechanisms
Alvarez-Rivera, E., Ortiz-Hernández, E. J., Lugo, E., Lozada-Reyes, L. M., & Boukli, N. M. (2023) · Proteomes · doi:10.3390/proteomes11030022 · Cited by 1
Development of a Small Molecule Downmodulator for the Transcription Factor Brachyury
Chase, D. H., Bebenek, A. M., Nie, P., Jaime‐Figueroa, S., Butrin, A., Castro, D. A., Hines, J. F., Linhares, B. M., & Crews, C. M. (2024) · Angewandte Chemie · doi:10.1002/ange.202316496 · Cited by 1
Global Profiling Lysine Reactivity and Ligandability with Oxidant‐Triggered Bioconjugation Chemistry
Zhou, M., Li, S., Tan, Y., Huang, W., Li, Y.-F., Yuan, X., & Li, Z. (2024) · Angewandte Chemie · doi:10.1002/ange.202418473 · Cited by 1
A CRISPR-Cas13d cancer therapeutic enables selective elimination of uveal melanoma
Stauber, D., Sosnick, L., Ma, Y., Pimcharoen, S., Lawanprasert, A., Murthy, N., Myung, D., & Qi, L. S. (2026) · Molecular therapy. Oncology · doi:10.1016/j.omton.2026.201151 · Cited by 2
Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery
Hendershot, J. C., Smith, A. E., & Werfel, T. A. (2019) · Journal of Visualized Experiments · doi:10.3791/59549 · Cited by 1
Deubiquitinase Inhibitors: An Emerging Therapeutic Class
Magin, R. S., Doherty, L. M., & Buhrlage, S. J. (2020) · Royal Society of Chemistry eBooks · doi:10.1039/9781839160691-00234 · Cited by 1
Glyco-Nanomedicines and Their Applications in Cancer Treatment
Diaz‐Dussan, D., Kumar, P., & Narain, R. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819475-1.00066-3 · Cited by 1
Targeting RNA polymerase II Mediator subunits in cancer therapy
Singh, H. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2100115118 · Cited by 1
Using the Structural Kinome to Systematize Kinase Drug Discovery
Zhao, Z., & Bourne, P. E. (2021) · Biochemistry · doi:10.5772/intechopen.100109 · Cited by 1
An “-omycs” Toolbox to Work with MYC
Whitfield, J. R., & Soucek, L. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1476-1_1 · Cited by 1
Self-citation
Targeting MYC to Combat Pancreatic Cancer
Liu, Y., Gan, Y., Chen, J.-Z., Jiang, Y., Huang, F., & Tang, D. (2022) · Journal of Exploratory Research in Pharmacology · doi:10.14218/jerp.2021.00015 · Cited by 1
Nonsurgical Management of Cholangiocarcinoma
Breen, M. J., Ahmed, O. S., Owen, J., & Liao, C. (2022) · Springer eBooks · doi:10.1007/978-3-030-41683-6_16 · Cited by 1
RETRACTED ARTICLE: Development of new c-Met inhibitors and application of corresponding multitarget tyrosine kinase inhibitors in tumor therapy
Zeng, X., Hu, Y., Xu, Z. P., Wu, X. O., Xiong, Y., & Liu, S. (2023) · Soft Computing · doi:10.1007/s00500-023-08664-1 · Cited by 1
Retracted
Oncogenic Wnt/STOP signaling regulates ribosome biogenesis in vivoPreprint
Madan, B., Harmston, N., Nallan, G., Montoya, A., Faull, P. A., Petretto, E. G., & Virshup, D. M. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/326819 · Cited by 1
Some chinks in RAS armor
Azmi, A. S. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.08.005 · Cited by 1
Editorial overview: Peptides in cancer
Whitfield, J. R., & Soucek, L. (2019) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2019.06.001 · Cited by 1
Self-citation
TCGA DEPMAP – Mapping Translational Dependencies and Synthetic Lethalities within The Cancer Genome AtlasPreprint
Shi, X., Gekas, C., Verduzco, D., Petiwala, S. M., Jeffries, C. T., Lu, C., Murphy, E., Anton, T., Vo, A. H., Xiao, Z., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.03.24.485544 · Cited by 1
MNT suppresses T cell apoptosis via BIM and is vital for MYC-driven T lymphomagenesisPreprint
Nguyen, H. V., Vandenberg, C. J., Robati, M., Ng, A. P., & Cory, S. (2022) · Research Square · doi:10.21203/rs.3.rs-1555936/v1 · Cited by 1
Targeted degradation of IKZF2 for cancer immunotherapyPreprint
Solomon, J. M., Bonazzi, S., d'Hennezel, E. B., Beckwith, R. E. J., Xu, L., Fazal, A., Magracheva, A., Ramesh, R., Cernijenko, A., Antonakos, B., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1531006/v1 · Cited by 1
Using Artificial Intelligence forde novoDrug Design and Retrosynthesis
Arora, R. R., Brosse, N., Descamps, C., Devaux, N., Huu, N. D., Gendreau, P., Gaston‐Mathé, Y., Parrot, M., Perron, Q., & Tajmouati, H. (2024) · Wiley eBooks · doi:10.1002/9783527840748.ch12 · Cited by 2
Inflammasome-Inhibiting Nanoligomers are Neuroprotective Against Space-Induced Pathology in Healthy and Diseased 3D Human Motor and Pre-Frontal Cortex Brain OrganoidsPreprint
Sharma, S., Gilberto, V. S., Rask, J. C., Chatterjee, A., & Nagpal, P. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.03.19.585802 · Cited by 1
Targeting oncogenic K-Ras mutants with a small-molecule degrader through Nedd4-1Preprint
Zeng, T., Jiang, T., Zhang, B., Zhang, T., Dai, W., Yin, X., Li, Y., Wu, C., Wu, Y., Chi, X., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.04.26.591418 · Cited by 1
Nanoparticle-mediated delivery of peptide-based degraders enables targeted protein degradationPreprint
Alabi, C. A., Ghosal, S., Robertus, C. M., Wang, J., Chan, H., Alamgir, A., & Almonte, J. (2024) · Research Square · doi:10.21203/rs.3.rs-3797623/v1 · Cited by 1
The theory of massively repeated evolution and full identifications of Cancer Driving Nucleotides (CDNs)Preprint
Zhang, L., Deng, T., Liufu, Z., Liu, X., Chen, B., Hu, Z., Liu, C., Tracy, M. E., Lu, X., Wen, H., et al. (2024) · eLife · doi:10.7554/elife.99340.2 · Cited by 1
On the discovered Cancer Driving Nucleotides (CDNs)–Distributions across genes, cancer types and patientsPreprint
Zhang, L., Deng, T., Liufu, Z., Chen, X., Wu, S., Liu, X., Shi, C., Chen, B., Hu, Z., Cai, Q., et al. (2024) · eLife · doi:10.7554/elife.99341.2 · Cited by 1
PepCCD: A Contrastive Conditioned Diffusion Framework for Target-Specific Peptide GenerationPreprint
Zhang, J., Zhou, Y., Zhu, T., & Zhu, Z. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.01.673427 · Cited by 1
Tryptoline Stereoprobe Elaboration Identifies Inhibitors of the GRPEL1-HSPA9 Chaperone ComplexPreprint
Hayward, R. E., Berkeley, R. F., Gao, Z., Garhammer, M., Morizono, M. A., Njomen, E., Li, H., DeMeester, K. E., Cociorva, V., Herzik, M. A., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.20.683548 · Cited by 1
Binding Paths: Describing Small Molecule Interactions with Disordered Proteins via a Markov State ModelPreprint
Louet, A. A. B., Hummer, G., & Vendruscolo, M. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.19.688850 · Cited by 2
Navigating the Cancer Transcriptome by Decoding Divergent Oncogenic States
Amin, S. B., & Verhaak, R. G. W. (2017) · Cell Systems · doi:10.1016/j.cels.2017.08.006
The USP28-ΔNp63 axis is a vulnerability of squamous tumoursPreprint
Prieto‐Garcia, C., Hartmann, O., Reissland, M., Braun, F., Fischer, T., Walz, S., Fischer, A., Calzado, M. A., Orian, A., Rosenfeldt, M. T., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/683508
Experimental and Computational Tools for Single Cell Analysis in Cancer Diagnostics
Vaithiyanathan, M. (2019) · doi:10.31390/gradschool_dissertations.5137
MYC’xing it up: zebrafish B ALL models provide insight into MYC-driven disease and relapse
da Bandeira, D. S., & Clements, W. K. (2020) · Oncotarget · doi:10.18632/oncotarget.27644
Chemical Probes to Control RNA Function
François‐Moutal, L., Miranda, V. G., Sandino, M., & Khanna, M. (2020) · Royal Society of Chemistry eBooks · doi:10.1039/9781839160745-00214
PANCREATIC CANCER, CURRENT THERAPEUTIC APPROACHES AND POSSIBLE PROSPECTS
Bykova, E. A., Falaleeva, N. A., & Grivtsova, L. Y. (2020) · Russian Journal of Biotherapy · doi:10.17650/1726-9784-2020-19-4-18-28
Small-molecule Inhibitors of Myc–Max Interaction and DNA Binding
Fletcher, S., & Prochownik, E. V. (2020) · Royal Society of Chemistry eBooks · doi:10.1039/9781788016544-00302
Targeting Positive Cofactor 4 induces autophagic cell death in MYC-expressing diffuse large B cell lymphomaPreprint
Ma, L., Gong, Q., Chen, Z., Wang, Y., Tan, X., Liu, Y., Wang, Y., Liu, G., Fu, J., Xie, M., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-421070/v1
Targeted Intervention of eIF4A1 Promotes EMT and Metastasis of Pancreatic Cancer Cells through c-MYC/miR-9 SignalingPreprint
Zhao, Y., Wang, Y., Chen, W., Bai, S., Wang, P., Zheng, M., Yang, Y., Cheng, B., & Luan, Z. (2021) · Research Square · doi:10.21203/rs.3.rs-907935/v1
Modulação do fator de transcrição TBX2 como nova estratégia anticâncer: estudo baseado na atividade biológica de cromomicina A>sub<5>/sub< em células melanoma.
Sahm, B. D. B. (2020) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.42.2020.tde-30092020-102358
Faculty Opinions recommendation of How We Think about Targeting RNA with Small Molecules.
Lowe, J. A., III (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.737636298.793572902

Authors: Dang, C. V., Reddy, E. P., Shokat, K. M., & Soucek, L.
Affiliations: The Wistar Institute (US)
Icahn School of Medicine at Mount Sinai (US)
Howard Hughes Medical Institute (US)
Institució Catalana de Recerca i Estudis Avançats (ES)
Corresponding author: Dang, Chi V.
Reddy, E. Premkumar
Shokat, Kevan M.
Soucek, Laura
ORCID: Dang, Chi V.
Reddy, E. Premkumar
Shokat, Kevan M.
Soucek, Laura
Venue: Nature Reviews Cancer
Publisher: Springer Science and Business Media LLC
Published: 2017-06-23
Volume: 17
Issue: 8
Pages: 502-508
ISSN: 1474-175X (ISSN-L)
1474-1768
DOI: 10.1038/nrc.2017.36
PMC: PMC5945194
OpenAlex: W2692768525
Cited by: 927
References: 57
Citations by year: 2026: 93 · 2025: 113 · 2024: 125 · 2023: 110 · 2022: 121 · 2021: 121 · 2020: 113 · 2019: 63 · 2018: 58 · 2017: 10
FWCI: 6.26
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
Locations: Nature reviews. Cancer (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
eScholarship (California Digital Library) (submittedVersion)
Funders: National Cancer Institute (R01CA057341, R01CA158209, R01CA051497)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
Keywords: oncogenic Ras, MYC oncogene, oncogene targeting, anticancer drug development
MeSH terms: Antineoplastic Agents, Humans, Neoplasms, Receptors, Androgen, Oncogene Proteins, Fusion, Proto-Oncogene Proteins c-myc, NF-kappa B, ras Proteins, Proto-Oncogene Proteins c-myb, Drug Discovery, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Drugging the ‘undruggable’ cancer targets

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks